Competitive Target Interactions

A competitive target interaction occurs when two drugs bind reversibly to the same site on a molecular target, so that the presence of one reduces the binding, and therefore the effect, of the other. Because the binding is reversible, the interaction is surmountable: raising the concentration of one drug can overcome the other. This is the receptor-level basis of competitive antagonism, the most rigorously quantified pharmacodynamic interaction.

Definition

A competitive target interaction is a reversible interaction in which two drugs compete for the same binding site on a molecular target, the occupancy of one diminishing that of the other; in the agonist-antagonist case it produces a surmountable, parallel shift of the agonist's concentration-response curve.

Scope

This topic covers competition between drugs for a shared binding site on a receptor or other molecular target: the reversible, surmountable nature of the interaction, its hallmark parallel rightward shift of the agonist concentration-response curve, and its quantification by Schild analysis (the Schild plot and pA2). It is a receptor-pharmacology reference and does not provide drug-specific or dosing guidance.

Core questions

• What distinguishes competitive from non-competitive interaction at a target?
• Why is competitive antagonism described as surmountable?
• How does competition shift the agonist concentration-response curve?
• How does Schild analysis quantify the interaction?
• What do the pA2 and the Schild slope tell us?

Key concepts

• Shared binding site competition
• Reversible, surmountable interaction
• Parallel rightward curve shift
• Dose-ratio
• Schild plot and pA2
• Competitive versus non-competitive (insurmountable) antagonism

Key theories

Schild analysis

Quantifies reversible competitive antagonism from the rightward shift of agonist concentration-response curves: plotting the log of the dose-ratio minus one against antagonist concentration yields a line whose intercept gives the pA2 and whose slope of unity confirms simple competition.

Mechanisms

When two ligands bind reversibly to the same site, occupancy by one lowers the fraction of target available to the other in a concentration-dependent way. For an agonist opposed by a competitive antagonist, the result is a parallel rightward displacement of the agonist concentration-response curve with no reduction in maximal response, because enough additional agonist can always outcompete the antagonist (surmountability). Schild's analysis captures this quantitatively: the dose-ratio, the factor by which the agonist concentration must be raised to restore a given response, increases linearly with antagonist concentration. The Schild plot of log(dose-ratio minus one) against log antagonist concentration ideally has unit slope, and its x-intercept defines the pA2, a concentration-independent measure of antagonist potency at that target. Deviations from unit slope or from surmountability signal departures from simple competition.

Clinical relevance

Competitive target interactions explain why two drugs acting at the same receptor can blunt or restore each other's effect, a recurring theme when appraising receptor-acting drug combinations. This entry describes the receptor-pharmacology principle and its measurement; it is a conceptual reference and not a guide to specific combinations, dosing, or treatment decisions.

Evidence & guidelines

The foundational evidence is experimental receptor pharmacology: Schild (1949) introduced the pAx scale, and Arunlakshana and Schild (1959) established the quantitative analysis of competitive antagonism that bears Schild's name. The principle is consolidated in standard pharmacology references (Ritter et al., 2019). These are methodological and textbook sources rather than clinical guidelines.

History

Quantitative receptor antagonism emerged from mid-twentieth-century work on the dose-ratio. Schild introduced the pAx scale in 1949, and with Arunlakshana provided the canonical 1959 treatment defining the Schild plot and pA2. The approach became the standard tool for classifying antagonists and characterising receptors, and it remains a reference method in receptor pharmacology.

Debates

Interpreting non-unit Schild slopes

A Schild plot slope departing from unity indicates that simple reversible competition does not fully describe the system (for example, multiple receptor populations, non-equilibrium conditions, or non-competitive components), complicating estimation of antagonist potency.

Key figures

• Heinrich O. Schild
• O. Arunlakshana
• John H. Gaddum

Seminal works

• schild-1949
• arunlakshana-schild-1959

Frequently asked questions

Why is competitive antagonism called 'surmountable'?

Because the binding is reversible, increasing the agonist concentration can outcompete the antagonist and restore the full maximal response; the antagonism can be overcome, which is why the concentration-response curve shifts right in parallel without a lower ceiling.

What is the pA2?

The pA2 is the negative logarithm of the antagonist concentration that requires a doubling of the agonist concentration to maintain a given response. Derived from the Schild plot, it is a concentration-independent measure of competitive antagonist potency at a receptor.